Table 1 Patient characteristics
Categorical characteristic | 3DCRT n = 115 | IG-IMRT n = 388 | P value |
|---|---|---|---|
No patients (%) | No patients (%) | ||
Performance status | 0.180 | ||
0 | 110 (96) | 367 (95) | |
1 | 5 (4) | 21 (5) | |
Comorbidity* | 0.070 | ||
Yes | 66 (60) | 215 (56) | |
No | 44 (40) | 166 (44) | |
Smoking# | 0.091 | ||
Yes | 30 (32) | 106 (29) | |
No | 65 (68) | 255 (71) | |
T-stage | 0.190 | ||
≤T2a | 19 (17) | 96 (25) | |
T2b | 3 (2) | 10 (2) | |
≥T2c | 92 (81) | 281 (73) | |
Gleason score | <0.001 | ||
5-6 | 42 (44) | 49 (13) | |
7 | 21 (22) | 197 (51) | |
8-10 | 33 (34) | 141 (36) | |
Adjuvant ADT | 0.019 | ||
Yes | 72 (88) | 350 (95) | |
No | 10 (12) | 20 (5) | |
Type of ADT | 0.054 | ||
GnRH agonist | 100 (89) | 365 (95) | |
Antiandrogen | 12 (11) | 21 (5) | |
Continuous characteristic | Median (range) | Median (range) | P value |
Age (y) | 63 (52–75) | 66 (49–76) | <0.001 |
PSA (ng/ml) | 32.7 (4.2-150) | 24.9 (4.2-200) | <0.001 |
PPB† (%) | 75 (17–100) | 67 (5–100) | 0.006 |
Follow-up (yr) | 8.2 (0.1-12.5) | 3.5 (0.3-7.1) | <0.001 |